QNCX
Quince Therapeutics, Inc.
Key Financials
Operating Income
$-58068000
↓ 1.4%
Net Income
$-83979000
↓ 47.8%
EPS (Diluted)
$-1.68
↓ 28.2%
Total Liabilities
$129.2M
↑ 53.2%
Total Assets
$93.5M
↓ 18.3%
Cash & Equivalents
$5.8M
↓ 6.5%
Shareholders' Equity
$-35714000.00
↓ 218.5%
Long-term Debt
$0.00
↓ 100.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| 8-K | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| S-3/A | 8/5/2026 | View on SEC |
| SCHEDULE 13G | 8/4/2026 | View on SEC |
| 8-K | 7/31/2026 | View on SEC |
| PRE 14A | 7/31/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | QNCX |
| Company Name | Quince Therapeutics, Inc. |
| CIK | 1662774 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | CA |
| Phone | 415-910-5717 |